Atomwise
Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery
The APEX Protocol throughput claim — 10 billion compounds in under 30 seconds — is a real one, and the NVIDIA co-authorship gives it more credibility than most vendor speed numbers. But Atomwise is a co-development shop: you get programs, not software seats, aimed at immune and inflammatory disease. If you want to test the model yourself or work outside that therapeutic lane, take a pass.
Last checked 17h ago · cite: rightaichoice.com/tools/atomwise
- Pharma companies hunting first-in-class small molecules for immune and inflammatory disease
- Funded biotechs with a defined target who want a discovery partner, not a software seat
- Discovery teams whose internal screening has stalled and need novel chemotypes from virtual space
- Groups that can run a co-development program with negotiated IP and milestone terms
- Researchers who require open-source algorithms or a public validation set to reproduce results
- Programs working on biologics, cell therapies, or non-immune small-molecule targets
- Teams that want to license and run the ML stack in-house on their own infrastructure
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Atomwise if you need to run a model on your own target today without a co-development agreement, or if your program targets biologics, cell therapies, or non-immune small molecules.
Co-development partnerships typically carry milestone and royalty obligations negotiated up front, so the headline 'no subscription' framing hides downstream economics tied to program success.
Atomwise sells discovery partnerships rather than seats, so it sits in a different budget line than tooling vendors. Funded biotechs with an active raise and pharma discovery groups can absorb the partner model; seed-stage labs and academic groups cannot, and should look at software-based virtual screening instead.
In short
Atomwise — Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery. Best for Pharma companies hunting first-in-class small molecules for immune and inflammatory disease, Funded biotechs with a defined target who want a discovery partner, not a software seat, Discovery teams whose internal screening has stalled and need novel chemotypes from virtual space. Contact Sales pricing.
No head-to-head comparison for Atomwise yet — the alternatives below are the closest matches we list.
What people actually say about Atomwise — is it worth it?
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
7 mentions across 2 sources (YouTube, Product Hunt) · researched Aug 29, 2026.
Average across the 2 sources that answered — each source counts once, not each post.
- +Screens 10 billion compounds in under 30 seconds via APEX Protocol
- +Focuses on novel immune-disease targets traditional methods miss
- +End-to-end pipeline from screening to candidate nomination
- +Inclusion in top-AI-pharma lists boosts credibility in industry
- +Co-development partnerships available for early-stage programs
- −No demonstrated success in human clinical trials yet
- −Pricing is opaque—requires contacting sales, no self-service
- −No public, independently verified validation data
- −Requires advanced computational and pharma expertise
- −Aimed only at large pharma, not small teams or academics
- • No public pricing; likely requires significant upfront commitment
- • Data-sharing and IP terms may affect rights to discovered compounds
Viability Score
How well maintained and how widely used is Atomwise? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- APEX Protocol virtual screening: 10 billion compounds in under 30 seconds (published Nov 2025 with NVIDIA)
- ML-driven exploration of chemical space for novel, drug-like molecules
- Ultra-fast screening of hyper-scalable virtual libraries
- Small-molecule discovery focused on immune and inflammatory diseases
- Binding affinity prediction for candidate molecules
- Drug-likeness prediction to filter viable leads
- First- and best-in-class drug candidate program design
- Hit identification from virtual libraries beyond traditional compound sets
- End-to-end drug discovery pipeline support via co-development
- Co-development partnership model for early-stage AI-generated candidates
- Programs targeting immune and inflammatory therapeutic areas
About Atomwise
Numerion Labs — the company still widely known as Atomwise — runs an AI superplatform that searches chemical space for novel, drug-like small molecules that conventional screening libraries don't contain. Its research programs target immune and inflammatory diseases, with candidates positioned for first- and best-in-class potential rather than incremental follow-ons. The technical headline is the APEX Protocol, published 12 November 2025 and co-authored with NVIDIA, which screens 10 billion virtual compounds in under 30 seconds. For teams whose bottleneck is virtual screening throughput, that's the number that matters: brute-force docking at that scale is normally a compute-budget problem, and collapsing it to seconds changes how many campaigns you can realistically iterate on in a quarter. Beyond raw throughput, the platform covers binding affinity prediction, drug-likeness prediction, and end-to-end support from hit identification through early-stage candidates — the machine-learning layer that turns a hyper-scalable virtual library into something a medicinal chemist can act on. Atomwise sells this through co-development partnerships rather than a self-service subscription: you bring a target or a disease area, and the two organizations run the program together. The fit is large pharma and funded biotech groups with small-molecule immune programs. Treat it as a discovery partner you sign, not a tool you log into.
Behind the Verdict
The APEX Protocol matters for one reason: it moves virtual screening from a scheduled compute job to something closer to interactive. On paper, screening 10 billion compounds in under 30 seconds with NVIDIA co-authorship is the kind of throughput claim that, if it holds in practice, changes how many campaigns a discovery team can cycle through in a quarter. We'd want to see it on a target we already understand before committing a program. Pick Atomwise when you have a defined small-molecule target in immune or inflammatory disease and your internal screening has stalled — either the chemotypes aren't novel enough or the compute budget can't cover the library you'd need. The co-development structure makes sense here: you're buying a program and a partner's ML stack, not a seat license. Pass if you need reproducibility on open data, a public validation set, or the ability to run the model yourself. That's not what this is. Also pass if your program is biologics, cell therapy, or a non-immune small-molecule target — the therapeutic focus is genuinely narrow. The closest comparison is Schrödinger: broad software you license and run in-house. Atomwise is the inverse — you hand over the target and they run the discovery with you. Two very different commitments, and only one of them puts a software stack on your machines. Where it bites: co-development means governance, timelines, and IP terms negotiated up front. Nothing here is self-serve, and a partner review cycle sits between you and any result. Budget that time.
Researching Atomwise? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Atomwise actually fits — and what changes day-one when you adopt it.
Internal HTS and a commercial library screen have stalled against an immune target with no tractable hits. You bring the target to Atomwise, they run ML-driven virtual screening across a hyper-scalable library, and deliver novel chemotypes for your team to validate in-house.
Outcome: You get chemotypes outside your own screening library, with binding affinity and drug-likeness predictions attached, without buying additional wet-lab screening capacity first.
You want first-in-class small molecules against an inflammatory pathway where the existing chemical matter is well picked over. A co-development program with Atomwise gives you a second discovery engine running in parallel to your internal team.
Outcome: Parallel campaign throughput without standing up a new internal ML screening function, with program design aimed at first-in-class rather than fast-follow.
You need to assess the APEX Protocol's screening claim before your organization commits. Since there's no self-service trial, the evaluation happens through published research and target-specific discussions with the Atomwise team.
Outcome: A decision based on the November 2025 NVIDIA co-authored publication and program fit, rather than a hands-on benchmark against your own target.
Use Cases
- Screen billions of compounds computationally for novel hits against immune-inflammatory targets
- Optimize lead candidates for binding affinity and drug-likeness using AI predictions
- De-risk early-stage drug discovery by predicting molecule behavior in silico
- Co-develop first-in-class small-molecule drugs for immune diseases
Models Under the Hood
as of 2026-10-16
Limitations
- Atomwise's platform is accessible only through direct business partnerships; co-development is the delivery model, not a choice among options.
- Its therapeutic focus on immune and inflammatory diseases means the platform is not positioned for broader therapeutic areas.
- Because programs are partner-run, an outside researcher cannot reproduce the APEX Protocol numbers against a public validation set — the NVIDIA co-authorship is the main external signal.
- Programs move on partnership timelines.
as of 2026-09-30
Verification history
We have re-verified Atomwise 21 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
Showing the 6 most recent of 21 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Atomwise's pricing actually pencils out — and where peers do it cheaper.
Atomwise sells discovery partnerships rather than seats, so it sits in a different budget line than tooling vendors. Funded biotechs with an active raise and pharma discovery groups can absorb the partner model; seed-stage labs and academic groups cannot, and should look at software-based virtual screening instead.
Setup time & first value
How long it actually takes to get something useful out of Atomwise — broken out by persona, not the marketing-page minute.
For a partner organization, expect weeks to months from first conversation to running campaign — the work is target rationale, program scoping, and agreement, not deployment.
Switching to or from Atomwise
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From in-house virtual screening: bring your target and existing chemical matter; Atomwise runs ML-driven screening across a hyper-scalable library you can't assemble yourself.
- →From a commercial compound library screen: co-development covers hits outside standard screening sets, aimed at chemotypes your library doesn't contain.
- →From a stalled internal HTS campaign: hand off the target and use predicted binding affinity and drug-likeness to prioritize what to synthesize next.
- ↗To internal ML discovery tooling: if you build in-house virtual screening capacity, the chemotypes discovered in a co-development program remain yours to advance.
- ↗To a CRO-led discovery program: wet-lab validation and med-chem work can be handed to a CRO once Atomwise has delivered early-stage candidates.
- ↗To a different AI discovery partner: programs are target-scoped and partner-run, so switching vendors means restarting scoping around a new target or re-evaluating the same one.
Resources & Guides
Tutorials & Learning
YouTube returned 6 videos for “Atomwise”, and we withheld 6: 6 could not be judged, because “Atomwise” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about Atomwise.
Official links
Tools that pair well with Atomwise
Common stack mates teams adopt alongside Atomwise, with the specific reason each pairing earns its keep.
Iktos
Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.
Isomorphic Labs
Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.
Nimbus Therapeutics
Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.
Alternatives to Atomwise
View all
Iktos
Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.
Isomorphic Labs
Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.
Nimbus Therapeutics
Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.
Categories
Topics
Used Atomwise? Help shape our editorial sentiment research.